March 13, 2018

The American Society of Clinical Oncology (ASCO) and ASCO’s Conquer Cancer Foundation proudly announce the winners of ASCO's Special Awards, the Society's highest honors, and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around the world. 

March 1, 2018

Alexandria, Va. - Use of tests that assess genomic variants in circulating tumor DNA (ctDNA) is on the rise. A new joint review from the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) provides an assessment of evidence on ctDNA tests in oncology. It also lays out a framework for future research and clinical practice guidelines to help better inform clinical practice. 

February 20, 2018

ASCO Statement on JAMA Internal Medicine’s Cigarette, Cigar, and Pipe Use Mortality Risk Study

Statement from Bruce E. Johnson, MD, FASCO, President of the American Society of Clinical Oncology (ASCO)

February 16, 2018

ORLANDO, Fla. – Nine key studies featuring research on survivorship care will be presented at the 2018 Cancer Survivorship Symposium, taking place February 16-17 at the Hyatt Regency Grand Cypress in Orlando, Florida. These select abstracts discuss new insights for the care of patients after cancer treatment, including issues of cost, patient engagement, exercise, late effects of cancer, and insomnia

February 14, 2018

ALEXANDRIA, VA, FORT WASHINGTON, PA. – Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body’s immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.

February 12, 2018

ALEXANDRIA, Va. – A follow-up study to a randomized clinical trial reveals that exercising during adjuvant (post-surgery) chemotherapy helps people engage in more physical activity years later. Four years later, people with breast or colon cancer who had participated in an 18-week exercise program while receiving chemotherapy engaged in physical activity 142 minutes per week or 20 minutes per day more, on average, than those who did not participate in the exercise program. Researchers will present their findings at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 12, 2018

ALEXANDRIA, Va. – A pilot study of cancer survivors ages 11-15 suggests that a web-based, interactive intervention that provides rewards for exercising can motivate kids to stay physically active. Moderate to vigorous physical activity increased by an average of nearly 5 minutes a week in the group that used the intervention and decreased by an average of over 24 minutes in the control group. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 12, 2018

ALEXANDRIA, Va. – Cancer care guidelines recommend that cancer survivors who experience sexual dysfunction after cancer treatment use therapeutic aids to help improve their sexual health. However, a new study of 25 leading cancer centers found that 87% of the centers reported having no sexual aids available on site for men, and 72% reported having no aids for women. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 12, 2018

ALEXANDRIA, Va. – A new study suggests that a large percentage of adolescents and young adults (AYAs) who have been treated for cancer do not seek follow-up care after their primary treatment ends, despite its importance for long-term health. AYA cancer survivors are at increased risk for heart problems, infertility, and secondary cancers from cancer treatment.

February 12, 2018

ALEXANDRIA, Va. – New findings from a clinical trial of women with breast cancer suggest that guided exercise with a physical therapist after lymph node dissection helps women regain their range of arm motion more quickly. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.

February 9, 2018

The American Society of Clinical Oncology (ASCO) commends Congress for passing a continuing resolution that includes an important correction to the Merit-based Incentive Payment System. We are also pleased to see a budget deal that commits to at least a $2 billion funding increase for the National Institutes of Health (NIH) to reclaim America’s leadership in cancer research and continue building on our tremendous progress towards understanding, preventing, and treating cancer.

February 8, 2018
SAN FRANCISCO - Eight noteworthy studies exploring key research in the treatment of genitourinary cancers will be presented at the 2018 Genitourinary Cancers Symposium, taking place February 8-10 at the Moscone West Building in San Francisco, California. These abstracts investigate several approaches to the treatment and management of prostate, kidney, and bladder cancers. 
February 7, 2018

The American Society of Clinical Oncology (ASCO) today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.

February 5, 2018

ALEXANDRIA, Va. – In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth by about three months longer than sunitinib, another targeted therapy. The benefit of atezolizumab plus bevacizumab was greater for patients with PD-L1-positive tumors. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.

February 5, 2018

ALEXANDRIA, Va. – Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk for developing metastatic disease, and for whom no approved treatments exist. Men who received apalutamide had a 72% lower risk of metastasis or death than those who received placebo.